このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Halozyme Therapeutics 将来の成長

Future 基準チェック /56

Halozyme Therapeutics利益と収益がそれぞれ年間21.7%と15%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に84.2% 23.1%なると予測されています。

主要情報

21.7%

収益成長率

23.1%

EPS成長率

Biotechs 収益成長	24.7%
収益成長率	15.0%
将来の株主資本利益率	84.2%
アナリストカバレッジ	Good
最終更新日	20 Jun 2024

今後の成長に関する最新情報

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 23

Recent updates

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 23

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

Jan 26

These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Jan 10

Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Dec 14

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Sep 22

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

Jul 04

We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

May 09

Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

Mar 28

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Jan 23

Calculating The Intrinsic Value Of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Dec 09

Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Oct 24

Here's Why We Think Halozyme Therapeutics (NASDAQ:HALO) Might Deserve Your Attention Today

Sep 08

Halozyme Therapeutics raises $625M through convertible senior notes due 2028

Aug 16

Halozyme Therapeutics: One To Put On Your 'Shopping List' For The Next Market Sell-Off

Aug 03

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Jul 26

業績と収益の成長予測

NasdaqGS:HALO - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,393	664	N/A	N/A	6
12/31/2025	1,154	517	678	697	9
12/31/2024	987	401	553	565	10
3/31/2024	863	319	424	431	N/A
12/31/2023	829	282	373	389	N/A
9/30/2023	781	254	354	369	N/A
6/30/2023	774	234	293	306	N/A
3/31/2023	705	182	264	279	N/A
12/31/2022	660	202	235	240	N/A
9/30/2022	581	211	238	240	N/A
6/30/2022	487	366	290	292	N/A
3/31/2022	472	435	287	289	N/A
12/31/2021	443	403	298	299	N/A
9/30/2021	463	409	265	268	N/A
6/30/2021	412	229	150	152	N/A
3/31/2021	331	163	116	119	N/A
12/31/2020	268	129	53	55	N/A
9/30/2020	200	22	-24	-22	N/A
6/30/2020	180	-40	-60	-58	N/A
3/31/2020	164	-80	-89	-86	N/A
12/31/2019	196	-72	-89	-85	N/A
9/30/2019	203	-40	-55	-48	N/A
6/30/2019	182	-43	-43	-38	N/A
3/31/2019	178	-51	-36	-32	N/A
12/31/2018	152	-80	-54	-49	N/A
9/30/2018	281	46	91	93	N/A
6/30/2018	319	76	130	132	N/A
3/31/2018	318	68	132	134	N/A
12/31/2017	317	63	N/A	134	N/A
9/30/2017	166	-88	N/A	-35	N/A
6/30/2017	134	-120	N/A	-64	N/A
3/31/2017	134	-116	N/A	-60	N/A
12/31/2016	147	-103	N/A	-50	N/A
9/30/2016	160	-71	N/A	-50	N/A
6/30/2016	149	-67	N/A	-58	N/A
3/31/2016	159	-37	N/A	-36	N/A
12/31/2015	135	-32	N/A	-37	N/A
9/30/2015	113	-42	N/A	-23	N/A
6/30/2015	107	-38	N/A	-19	N/A
3/31/2015	82	-57	N/A	-44	N/A
12/31/2014	75	-68	N/A	-48	N/A
9/30/2014	57	-85	N/A	-62	N/A
6/30/2014	59	-84	N/A	-61	N/A
3/31/2014	55	-91	N/A	-56	N/A
12/31/2013	55	-83	N/A	-49	N/A
9/30/2013	64	-66	N/A	-51	N/A
6/30/2013	53	-67	N/A	-53	N/A

アナリストによる今後の成長予測

収入対貯蓄率: HALOの予測収益成長率 (年間21.7% ) は貯蓄率 ( 2.4% ) を上回っています。

収益対市場: HALOの収益 ( 21.7% ) はUS市場 ( 14.8% ) よりも速いペースで成長すると予測されています。

高成長収益: HALOの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: HALOの収益 ( 15% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: HALOの収益 ( 15% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: HALOの自己資本利益率は、3年後には非常に高くなると予測されています ( 84.2 %)。

Halozyme Therapeutics 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Price target increased by 11% to US$57.11

Halozyme Therapeutics, Inc. Updates Earnings Guidance for the Full Year 2024

Price target increased by 8.3% to US$51.44

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for 2024

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Recent updates

Halozyme Therapeutics, Inc. Announces argenx Receives FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy

Independent Director recently sold US$1.0m worth of stock

Independent Director notifies of intention to sell stock

Price target increased by 11% to US$57.11

Halozyme Therapeutics, Inc. Updates Earnings Guidance for the Full Year 2024

Halozyme Therapeutics: The Story Brightens

Investor sentiment improves as stock rises 19%

Senior VP & CTO exercised options and sold US$743k worth of stock

Price target increased by 8.3% to US$51.44

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for 2024

Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors

Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?

Halozyme Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Senior VP & Chief Technical Officer exercised options and sold US$606k worth of stock

Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics

Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?

Halozyme Therapeutics, Inc., Annual General Meeting, Apr 25, 2024

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares

Senior VP & Chief Technical Officer exercised options and sold US$612k worth of stock

Senior VP & Chief Technical Officer notifies of intention to sell stock

Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Full year 2023 earnings: EPS exceeds analyst expectations

President exercised options and sold US$735k worth of stock

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

President exercised options and sold US$601k worth of stock

Halozyme Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Halozyme Therapeutics: A Reasonable Value In An Overvalued Market

Halozyme Announces Argenx Receives Approval in Japan for Vyvdura®? Co-Formulated with Enhanze®? for Generalized Myasthenia Gravis

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023

Halozyme Announces Takeda Receives FDA Approval for Hyqvia® Co-Formulated with Enhanze® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Announces Roche Receives European Commission Approval of Tecentriq®? SC with ENHANZE®? Representing the EU's First Subcutaneous PD(L)1 Cancer Immunotherapy for Multiple Cancer Types

These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely

Senior VP & Chief Technical Officer exercised options and sold US$544k worth of stock

Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price

Senior VP & Chief Technical Officer notifies of intention to sell stock

Third quarter 2023 earnings: EPS exceeds analyst expectations

Halozyme Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Halozyme Therapeutics, Inc. Reports Positive Topline Results from the Phase 3 Checkmate-67T Trial Evaluating Subcutaneous (SC) Formulation of Opdivo (Nivolumab) with Enhanze

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery

Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Therapeutics, Inc Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

Independent Director recently sold US$875k worth of stock

Independent Director notifies of intention to sell stock

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2023

Halozyme Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Senior VP & Chief Technical Officer notifies of intention to sell stock

Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Positive Results Announces from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate

Senior VP & Chief Technical Officer notifies of intention to sell stock

Halozyme Announces argenx Receives FDA Approval for VYVGART Hytrulo With ENHANZE for Subcutaneous Use in Generalized Myasthenia Gravis

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2023

We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt

Senior VP & Chief Technical Officer notifies of intention to sell stock

Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?

Insufficient new directors

Price target decreased by 7.1% to US$52.11

Investor sentiment deteriorates as stock falls 16%

President notifies of intention to sell stock

Independent Director recently sold US$962k worth of stock

Chief Technical Officer notifies of intention to sell stock

Consensus EPS estimates fall by 10%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

President exercised options and sold US$1.1m worth of stock